TEVA · Healthcare · $45.8B
$39.31-0.73%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 61 Drug Manufacturers - Specialty & Generic peers
Quarterly Revenue Growth
“혁신 의약품 포트폴리오(AUSTEDO·AJOVY·UZEDY)가 전년 동기 대비 43% 성장하며 제네릭 REVLIMID 손실(전년 동기 3억 1,”
In the company's words · 2026 2분기 earnings call